HC Wainwright Reiterates Buy Rating for Pluristem Therapeutics (NASDAQ:PSTI)

Pluristem Therapeutics (NASDAQ:PSTI)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Wednesday, AnalystRatings.com reports. They currently have a $15.50 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 379.88% from the company’s previous close.

Several other research firms also recently weighed in on PSTI. LADENBURG THALM/SH SH assumed coverage on shares of Pluristem Therapeutics in a research report on Monday, July 22nd. They issued a “buy” rating on the stock. ValuEngine downgraded shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $9.25.

Pluristem Therapeutics stock traded up $0.03 during mid-day trading on Wednesday, hitting $3.23. The company’s stock had a trading volume of 23,200 shares, compared to its average volume of 72,100. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.23 and a current ratio of 2.74. Pluristem Therapeutics has a 12 month low of $3.17 and a 12 month high of $11.90. The business has a 50 day moving average price of $3.55 and a 200-day moving average price of $2.47.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. United Capital Financial Advisers LLC raised its position in Pluristem Therapeutics by 37.8% in the second quarter. United Capital Financial Advisers LLC now owns 85,733 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 23,533 shares during the period. Jane Street Group LLC raised its position in shares of Pluristem Therapeutics by 28.1% during the 2nd quarter. Jane Street Group LLC now owns 153,322 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 33,630 shares during the period. Verition Fund Management LLC bought a new stake in shares of Pluristem Therapeutics during the 2nd quarter valued at $231,000. Nikko Asset Management Americas Inc. raised its position in shares of Pluristem Therapeutics by 102.8% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,882,401 shares of the biotechnology company’s stock valued at $1,168,000 after purchasing an additional 954,161 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Pluristem Therapeutics by 107.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,882,401 shares of the biotechnology company’s stock valued at $1,168,000 after purchasing an additional 974,306 shares during the period. Institutional investors and hedge funds own 71.33% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Featured Article: Capital gains and your 401(k) or IRA

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.